Metrics as of 10/17/2026, 08:30 AM (Berlin time), refresh in progress.
Retension Pharmaceuticals Inc.
Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure…
1D
+15.2%
1W
+33.6%
1M
–
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
FREE FLOAT
–
FLOAT SHARES
–
AVG. DAILY VOLUME (30D)
253,633
BERENDT MICHAEL J
BERENDT MICHAEL J
BERGER FRANKLIN M
BERGER FRANKLIN M
Bisson Sabine
Retension Pharmaceuticals Inc. is a company in the Healthcare sector, Medical - Pharmaceuticals industry, headquartered in United States.
The CEO is Eric L. Keller, the company employs around 12 people.
The IPO was on 09/10/2026; the stock trades on NASDAQ under the ticker RTSN.
No, Retension Pharmaceuticals currently does not pay a dividend.
Clicking "Analyze stock" lets five strategies assess Retension Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.